Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747390 · ClinicalTrials.gov registry record · Phase 1
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
A Phase 1 study of Squamous Cell Carcinoma and Human Papilloma Virus, sponsored by Ryan Carey.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06747390: Recruiting Phase 1 study of Squamous Cell Carcinoma and Human Papilloma Virus, sponsored by Ryan Carey.
NCT06747390 is a Phase 1 study of Squamous Cell Carcinoma and Human Papilloma Virus that is actively recruiting participants, run by Ryan Carey. The registered enrollment target is 30 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06747390, a Phase 1 study of Squamous Cell Carcinoma and Human Papilloma Virus, is actively recruiting participants, sponsored by Ryan Carey.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Based on evidence that the local anesthetic lidocaine may have anticancer effects, this study will assess the safety and efficacy of intratumoral lidocaine injection at the time of direct laryngoscopy prior to TransOral Robotic Surgery (TORS) and neck dissection for oropharyngeal squamous cell carcinoma (OPSCC). The primary objective of the study is to determine if intratumoral lidocaine injection is safe and causes a major pathologic treatment effect in the primary tumor following surgical resection. The secondary objectives will be to determine if intratumoral lidocaine injection improves locoregional control rates, progression-free survival, metastasis-free survival, and overall survival compared to no injection.
Primary Outcome
Adverse events (AE) and Serious Adverse Events (SAE) will use the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The CTCAE v.5 utilizes a five point scale to report AEs, defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
Conditions Studied
Interventions
- DRUG Lidocaine 1% Injectable Solution
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 1 |
What NCT06747390 shows while recruiting
NCT06747390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (71% lower).
The record links to 4 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Lidocaine 1% Injectable Solution is the first listed.
NCT06747390 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06747390 about?
NCT06747390 is a clinical study titled "Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery". Based on evidence that the local anesthetic lidocaine may have anticancer effects, this study will assess the safety and efficacy of intratumoral lidocaine injection at the time of direct laryngoscopy prior to TransOral Robotic Surgery (TORS) and neck dissection for oropharyngeal squamous cell carci...
What is the current status of trial NCT06747390?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-04-23. Estimated completion is 2028-11-01.
What conditions does trial NCT06747390 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Human Papilloma Virus, Oropharyngeal Cancer, Oropharyngeal Squamous Cell Carcinoma (OPSCCA).
What interventions are being tested in trial NCT06747390?
The interventions under investigation include: Lidocaine 1% Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT06747390?
This trial is sponsored by Ryan Carey, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747390 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06747390's enrollment target sits among peer trials
30 31st of 47 higher than 14 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
RECRUITING · Phase 1
-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
ACTIVE NOT RECRUITING · Phase 1
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
-
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
COMPLETED · Phase 1
-
Pembrolizumab in Combination With CRT for LA-SCCHN
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI